Crewe Advisors’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $498K | Buy |
1,376
+41
| +3% | +$14K | 0.04% | 144 |
|
|
2026
Q1 | $470K | Buy |
1,335
+30
| +2% | +$10.7K | 0.04% | 131 |
|
|
2025
Q4 | $427K | Buy |
1,305
+10
| +0.8% | +$3.17K | 0.04% | 140 |
|
|
2025
Q3 | $365K | Buy |
1,295
+1
| +0.1% | +$290 | 0.03% | 145 |
|
|
2025
Q2 | $361K | Buy |
1,294
+17
| +1% | +$4.82K | 0.05% | 112 |
|
|
2025
Q1 | $398K | Sell |
1,277
-6
| -0.5% | -$1.77K | 0.06% | 95 |
|
|
2024
Q4 | $334K | Sell |
1,283
-169
| -12% | -$50.1K | 0.05% | 109 |
|
|
2024
Q3 | $468K | Buy |
1,452
+6
| +0.4% | +$1.96K | 0.05% | 85 |
|
|
2024
Q2 | $452K | Sell |
1,446
-39
| -3% | -$11.5K | 0.05% | 112 |
|
|
2024
Q1 | $422K | Buy |
+1,485
| New | +$435K | 0.05% | 111 |
|
|
2023
Q3 | – | Sell |
-1,279
| Closed | -$284K | – | 603 |
|
|
2023
Q2 | $284K | Sell |
1,279
-16
| -1% | -$3.71K | 0.04% | 110 |
|
|
2023
Q1 | $313K | Sell |
1,295
-45
| -3% | -$11K | 0.05% | 117 |
|
|
2022
Q4 | $352K | Buy |
1,340
+698
| +109% | +$187K | 0.06% | 98 |
|
|
2022
Q3 | $145K | Sell |
642
-53
| -8% | -$12.8K | 0.03% | 181 |
|
|
2022
Q2 | $169K | Buy |
695
+146
| +27% | +$35.8K | 0.04% | 151 |
|
|
2022
Q1 | $133K | Buy |
549
+329
| +150% | +$75.6K | 0.03% | 151 |
|
|
2021
Q4 | $49K | Hold |
220
| – | – | 0.01% | 187 |
|
|
2021
Q3 | $47K | Hold |
220
| – | – | 0.01% | 153 |
|
|
2021
Q2 | $54K | Hold |
220
| – | – | 0.01% | 149 |
|
|
2021
Q1 | $55K | Hold |
220
| – | – | 0.01% | 145 |
|
|
2020
Q4 | $51K | Sell |
220
-74
| -25% | -$17.1K | 0.02% | 138 |
|
|
2020
Q3 | $75K | Buy |
294
+74
| +34% | +$18.3K | 0.04% | 99 |
|
|
2020
Q2 | $52K | Hold |
220
| – | – | 0.03% | 105 |
|
|
2020
Q1 | $45K | Hold |
220
| – | – | 0.03% | 96 |
|
|
2019
Q4 | $53K | Hold |
220
| – | – | 0.02% | 110 |
|
|
2019
Q3 | $43K | Sell |
220
-24
| -10% | -$4.61K | 0.02% | 124 |
|
|
2019
Q2 | $45K | Buy |
244
+22
| +10% | +$3.94K | 0.01% | 147 |
|
|
2019
Q1 | $42K | Buy |
222
+2
| +0.9% | +$382 | 0.01% | 127 |
|
|
2018
Q4 | $43K | Hold |
220
| – | – | 0.01% | 119 |
|
|
2018
Q3 | $46K | Hold |
220
| – | – | 0.04% | 125 |
|
|
2018
Q2 | $41K | Sell |
220
-138
| -39% | -$24.4K | 0.04% | 131 |
|
|
2018
Q1 | $61K | Buy |
358
+53
| +17% | +$9.73K | 0.06% | 100 |
|
|
2017
Q4 | $53K | Buy |
+305
| New | +$54K | 0.05% | 109 |
|
Other funds holding AMGN
FFM
Crewe Advisors's AMGN Position: Q2 2026 in Review
Crewe Advisors increased its Amgen (AMGN) stake by 3.1% in Q2 2026, buying an estimated $14K and bringing the position to 1,376 shares worth $498K. The position accounts for 0.04% of the portfolio, ranked #144.
Crewe Advisors first reported a position in AMGN in Q4 2017 and has held it in 33 quarters since. 1,447 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Crewe Advisors held 1,376 shares of Amgen worth $498K as of Q2 2026.
- Crewe Advisors bought 41 Amgen shares in Q2 2026, an estimated $14K.
- Amgen made up 0.04% of Crewe Advisors's portfolio in Q2 2026, its #144 holding.
- Crewe Advisors first reported a position in Amgen in Q4 2017 and has held it in 33 quarters since.
- 1,447 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.